Suven gets 4 patent approvals in key markets

27 May 2011 Evaluate

Suven Life Sciences has received four product patents from different countries for its new chemical entities (NCEs) which could be used in treating various central nervous system disorders. he four product patents, one from New Zealand, one from Australia, one from Korea and one from Europe are valid through 2025. With these new patents, the company now has eight patents from Europe, ten from New Zealand, nine from Australia and three from Korea for the NCEs

The company has received the approval for molecules which could be used in the treatment of CNS disorders like Parkinsons, Alzheimers and schizophrenia. Products out of these inventions may be out-licensed at various phases of clinical research like at phase I or phase II

crackcrack

Suven Life Sciences Share Price

128.85 -2.40 (-1.83%)
04-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1709.40
Dr. Reddys Lab 1109.75
Cipla 1415.55
Lupin 1971.10
Zydus Lifesciences 866.65
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...